Congressional Trader
Live

BMY congressional trades

17 matched disclosures

Track congressional trades for BMY
Tracked disclosures
17
Lawmakers
11
Buy / sell
7 / 10
Avg post-trade move
N/A
Latest filing 2026-06-11

BMY congressional trades snapshot

This page summarizes public STOCK Act disclosures involving BMY. It is useful for seeing which lawmakers reported BMY transactions, how many filings are visible, the buy/sell mix, and whether the newest public filing describes a recent or delayed trade.

Last updated

Jun 11, 2026

Data source

Public House and Senate STOCK Act disclosures normalized by Congressional Trader.

Key caveat

Filing date can trail transaction date. This page is for research and monitoring, not investment advice.

What the BMY congressional trade page shows

Congressional Trader tracks 17 public STOCK Act disclosures for BMYacross 11 lawmakers. This page separates purchases from sales, shows filing delays, and links each disclosure back to the individual politician profile when available.

The most recent BMY filing shown here was filed on Jun 11, 2026 by Mike Kelly as a sale. Related lawmakers include Julie Johnson, Gilbert Ray Cisneros, John James, Julia Letlow, Tommy Tuberville.

Top lawmakers for BMY

Julie Johnson3 filingsGilbert Ray Cisneros2 filingsJohn James2 filingsJulia Letlow2 filingsTommy Tuberville2 filingsGreg Landsman1 filingsJefferson Shreve1 filingsMike Kelly1 filingsRick Larsen1 filingsVal T. Hoyle1 filingsVirginia Foxx1 filings

Related paths

Alerts for BMYCongressional stock trading trackerLatest disclosuresHealthcare

Pro performance summary

Unlock 30/90-day post-trade summaries, committee overlap, and CSV-oriented research views for high-intent ticker research.

Compare Pro plans
Mike KellyR-PAHouse
No committee data
Filed Jun 11, 2026
Delay 35 days
View filing
BMY
Bristol-Myers Squibb Company
Sale
$15K - $50K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Julie JohnsonD-TXHouse
No committee data
Filed Jan 15, 2026
Delay 28 days
View filing
BMY
Bristol-Myers Squibb Company Common Stock
Sale
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Julia LetlowR-LAHouse
No committee data
Filed Jan 13, 2026
Delay 260 days
View filing
BMYNotable
Bristol-Myers Squibb Company Common Stock
Sale
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Julia LetlowR-LAHouse
No committee data
Filed Jan 13, 2026
Delay 447 days
View filing
BMYNotable
Bristol-Myers Squibb Company
Purchase
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Gilbert Ray CisnerosD-CAHouse
No committee data
Filed Jan 12, 2026
Delay 24 days
View filing
BMYNotable
Bristol-Myers Squibb Company Common Stock
Purchase
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Gilbert Ray CisnerosD-CAHouse
No committee data
Filed Dec 15, 2025
Delay 33 days
View filing
BMY
Bristol-Myers Squibb Company Common Stock
Purchase
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Val T. HoyleD-ORHouse
No committee data
Filed Sep 12, 2025
Delay 318 days
View filing
BMYNotable
Bristol-Myers Squibb Company Common Stock
Purchase
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Virginia FoxxR-NCHouse
No committee data
Filed Jul 3, 2025
Delay 9 days
View filing
BMY
Bristol-Myers Squibb Company
Sale
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Jefferson ShreveR-INHouse
No committee data
Filed Jun 22, 2025
Delay 41 days
View filing
BMY
Bristol-Myers Squibb Company Common Stock
Sale
$15K - $50K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Julie JohnsonD-TXHouse
No committee data
Filed May 14, 2025
Delay 43 days
View filing
BMY
Bristol-Myers Squibb Company Common Stock
Sale
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Greg LandsmanD-OHHouse
No committee data
Filed Apr 8, 2025
Delay 12 days
View filing
BMY
Bristol-Myers Squibb Company Common Stock
Sale
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Julie JohnsonD-TXHouse
No committee data
Filed Feb 12, 2025
Delay 28 days
View filing
BMY
Bristol-Myers Squibb Company Common Stock
Purchase
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
John JamesR-MIHouse
No committee data
Filed Sep 2, 2024
Delay 228 days
View filing
BMY
Bristol-Myers Squibb Company Common Stock
Sale
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
John JamesR-MIHouse
No committee data
Filed Sep 2, 2024
Delay 297 days
View filing
BMYNotable
Bristol-Myers Squibb Company
Purchase
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Tommy TubervilleR-ALSenate
No committee data
Filed May 15, 2024
Delay 42 days
View filing
BMYNotable
Bristol-Myers Squibb Company Common StockOption Type: PutStrike price:$50.00Expires:06/21/2024
Purchase
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Tommy TubervilleR-ALSenate
No committee data
Filed Feb 14, 2024
Delay 42 days
View filing
BMY
Bristol-Myers Squibb Company Common Stock
Partial sale
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade
Rick LarsenD-WAHouse
No committee data
Filed Jan 19, 2024
Delay 10 days
View filing
BMY
Bristol-Myers Squibb Company
Sale
$1K - $15K
Expert AnalysisPro
/ 100 Political Alpha

Upgrade to see committee overlap, performance context, and full expert analysis.

Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
Upgrade

FAQ

Which lawmakers traded BMY?

Recent BMY disclosures include Julie Johnson, Gilbert Ray Cisneros, John James, Julia Letlow, Tommy Tuberville.

What is the buy/sell mix for BMY?

The visible sample currently shows 7 purchases and 10 sales or partial sales.

Should I trade based on BMY disclosures?

No. This page summarizes public filings for research and monitoring. It is not investment advice.